Corporate Reputation of Pharma Companies, 2017-2018 - Patient Perspective of 202 Neurological Patient Groups - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "The Corporate Reputation of Pharma Companies, 2017 - The Patient Perspective - Neurological Edition" report has been added to ResearchAndMarkets.com's offering

State of relationships between neurological patient groups and the pharmaceutical industry

The 202 neurological patient groups worldwide responding to the 2017 survey on the Corporate Reputation of the Pharmaceutical Industry' were more positive about the industry's corporate reputation than their predecessors in 2016. 42% of 2017's respondent neurological patient groups stated that the pharma industry as a whole had an Excellent or Good corporate reputation - ranking the industry 3rd for corporate reputation out of nine healthcare sectors (compared with the equivalent 2016 figure of 28%, which ranked pharma 5th out of eight healthcare sectors in 2016).

One possible explanation for the industry's rise in corporate reputation among neurological patient groups in 2017 could be that the levels, or the quality (or both), of industry partnerships with neurological patient groups increased that year. In 2017, 40% of the neurological patient groups described pharma as Excellent or Good at patient-group partnerships, compared with 28% in 2016.

Views of neurological patient groups vary

The one major theme running through this neurological analysis, however, is the significant diversity in attitude between the neurological patient organisations - according to their neurological specialty. A chart in the report shows the different perspectives of the various types of neurological patient groups on the overall corporate reputation of the pharma industry for each of the 12 indicators of corporate reputation.

Key Topics Covered:

1. Executive Summary
2. Sector Analysis: Epilepsy; Multiple Sclerosis; And Parkinson's
3. The Relationships That Neurological Patient Groups Have With Pharma, 2017
4. Industry-Wide Findings From Neurological Patient Groups, 2017
5. Rankings Of The 27 Pharma Companies, 2017 V. 2016 Among Neurological Patient Groups Familiar With The Companies
6. Positionings Of 23 Pharma Companies, 2017 V. 2016 Among Neurological Patient Groups That Work/Partner With The Companies
7. Profiles Of The 27 Companies, 2017

Companies Mentioned

• AbbVie
• Acorda
• Allergan
• Almirall
• Amgen
• Astellas Pharma
• AstraZeneca
• Bayer
• Biogen
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Celgene
• Eisai
• Eli Lilly
• Grnenthal
• GSK
• Janssen
• Lundbeck
• Merck & Co/MSD
• Merck KGaA
• Novartis
• Pfizer
• Roche/Genentech
• Sanofi
• Takeda
• Teva
• UCB

For more information about this report visit https://www.researchandmarkets.com/research/x5d54d/corporate?w=4